Subclinical hyperthyroidism. Thyrotoxicosis, unspecified Hyperthyroidism NOS
Conditions
Interventions
Intervention 1: Intervention: Methimazole 5-10 mg/day po until the patient become euthyroid then 2.5-5 mg/day po maintenace dose for 1 year. Intervention 2: Control: Without any intervention for 1 yea
Treatment - Drugs
Intervention: Methimazole 5-10 mg/day po until the patient become euthyroid then 2.5-5 mg/day po maintenace dose for 1 year.
Control: Without any intervention for 1 year
Sponsors
Kurdistan university of medical sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Young women referred to Kurdistan nuclear medicine center for thyroid evaluation which has suppressed TSH and normal FT4 and FT3 without history of thyroid disorders. Exclusion criteria: Secondary osteoporosis, hypersensitivity to oral anti-thyroid drugs, discontinuation of 1 year follow-up
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thyroid function. Timepoint: 3-6-12 months after treatment. Method of measurement: TSH, freeT3, freeT4 measurement by IRMA & RIA methods. | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone mineral density. Timepoint: 12 months after treatment or follow-up. Method of measurement: Measuring BMD of lumbar vertebrae(L2-L4) and femoral neck by DXA method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSiamak Derakhshan M.D
Kurdistan university of medical science
Outcome results
None listed